FDA OKs new label expansions for Dupixent and Incyte’s Monjuvinews2025-06-20T14:15:46+00:00June 20th, 2025|Endpoints News|
Bavarian Nordic’s PRV goes for $160M; Biomea to advance GLP-1 into trialsnews2025-06-18T14:06:08+00:00June 18th, 2025|Endpoints News|
Prothena moves forward with layoffs; Aldeyra resubmits dry eye drug to FDAnews2025-06-17T15:11:04+00:00June 17th, 2025|Endpoints News|
Incyte’s promising thrombocythemia drug; Crescent Biopharma raises $200M in PIPEnews2025-06-16T14:40:26+00:00June 16th, 2025|Endpoints News|
Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy datanews2025-06-13T14:18:50+00:00June 13th, 2025|Endpoints News|
ADC Therapeutics reveals layoffs, $100M PIPE; Third Harmonic seeks buyer for assetnews2025-06-12T14:31:06+00:00June 12th, 2025|Endpoints News|
Lilly pledges more than $650M to muscle health biotech; Cogent gets $50Mnews2025-06-11T14:32:45+00:00June 11th, 2025|Endpoints News|
Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issuesnews2025-06-10T14:49:27+00:00June 10th, 2025|Endpoints News|
Avidity to seek accelerated approval for FSHD drug; Axsome to run another trialnews2025-06-09T14:44:56+00:00June 9th, 2025|Endpoints News|
Kelun’s $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kidsnews2025-06-06T14:09:09+00:00June 6th, 2025|Endpoints News|
